Remove Communication Remove Department of Veterans Affairs Remove Pharmaceutical Manufacturing
article thumbnail

Most Favored Nation Pricing is Back – With a Vengeance

FDA Law Blog: Biosimilars

It sets forth three directives: HHS shall consider facilitating direct-to-consumer purchasing programs for pharmaceutical manufacturers that sell their products to American patients at the most-favored-nation (MFN) price. MFN pricing reemerged in todays Executive Order, which goes well beyond the 2020 order. Within 30 days (i.e.,